Physician profile
Ali Amin
NPI 1770833147
$3,559.36
in general payments reported to CMS, 2019-2025
15 companies · $997 in 2025
The $997 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.32 · 2021: $140 · 2022: $494 · 2023: $698 · 2024: $1,213 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.99 |
| Education | $187.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,253.31 | 2022-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $783.55 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $680.03 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Glaxosmithkline, LLC. | $221.27 | 2021-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $142.94 | 2022-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $88.09 | 2022-2024 | Lupkynis |
| Ucb, INC. | $68.48 | 2022-2024 | Cimzia, Bimzelx |
| Pfizer INC. | $65.24 | 2022-2023 | |
| Lilly USA, LLC | $56.48 | 2022-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $55.10 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $43.50 | 2023-2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $38.86 | 2024 | Orencia |
| Sobi, INC | $25.54 | 2023 | |
| Genzyme Corporation | $24.04 | 2025 | |
| Genentech USA, INC. | $12.93 | 2023 | Rituxan, Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.